Revenue: The sum of all revenue fields included for a company's operating activities.
Supernus Pharmaceuticals, Inc. (SUPN) had Revenue of $165.45M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
|
Revenue |
$165.45M |
$22.50M |
|
$16.83M |
|
$148.63M |
|
$153.31M |
|
$12.14M |
|
$4.53M |
|
$16.67M |
|
$16.67M |
|
$22.50M |
|
$22.50M |
|
$22.50M |
|
$22.50M |
|
$12.14M |
|
$33.47M |
|
56.02M |
|
56.64M |
|
$0.40 |
|
$0.40 |
|
| Balance Sheet Financials | |
$738.87M |
|
$11.07M |
|
$643.54M |
|
$1.38B |
|
$286.36M |
|
-- |
|
$32.15M |
|
$318.50M |
|
$1.06B |
|
$465.57M |
|
$1.06B |
|
56.12M |
|
| Cash Flow Statement Financials | |
$89.13M |
|
$6.71M |
|
$-20.46M |
|
$69.33M |
|
$144.71M |
|
$75.38M |
|
$15.57M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
89.83% |
|
7.34% |
|
7.34% |
|
-- |
|
10.07% |
|
13.60% |
|
$88.35M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
0.38 |
|
1.17 |
|
76.61 |
|
2.11% |
|
4.83% |
|
1.63% |
|
2.11% |
|
$18.96 |
|
$1.56 |
|
$1.57 |
|